



# Scientific Journal of Immunology & Immunotherapy

## Review Article

# IL-35- and IL-10-Dependent Immunoregulatory Lymphocytes in Rheumatoid Arthritis -

**Raef Shams\* and Ehab M. Ali**

*Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta 31527, Egypt*

**\*Address for Correspondence:** Raef Shams, Biochemistry Division, Faculty of Science, Tanta University, Tanta 31527, Egypt, Tel: +2-01275114448; Fax: +2-0403350804; E-mail: raefshams@yahoo.com

**Submitted:** 11 September 2017; **Approved:** 25 September 2017; **Published:** 26 September 2017

**Cite this article:** Shams R, Ali EM. IL-35- and IL-10-Dependent Immunoregulatory Lymphocytes in Rheumatoid Arthritis. *Sci J Immunol Immunother.* 2017;2(1): 011-017.

**Copyright:** © 2017 Shams R, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

Several studies investigated the different therapeutic roles of T and B lymphocytes subsets in Rheumatoid Arthritis (RA). The disease pathogenesis implicates various cells subpopulations regarding  $T_H1$  and  $T_H17$  cells that produce pro-inflammatory cytokines as well as autoantibodies production by B cells. On the other hand, certain T and B lymphocytes negatively regulate the immune response by producing regulatory cytokines or by interaction with pathogenic subsets. Recent studies investigate that the therapeutic function of these cells is exerted by IL-10, IL-35 and TGF- $\beta$  regulatory cytokines production. IL-35 showed to restrict  $T_H1/T_H17$  differentiation and function, and expand the suppressive function of  $T_{Reg}$  and  $B_{Reg}$ . Furthermore, IL-35 promotes the conversion of  $T_{Reg}$  and  $B_{Reg}$  to IL-35-producers (iTr35 and IL-35 $^+$  $B_{Reg}$ , respectively). B cell-derived IL-10 not only suppresses IL-6 and IL-12 production by dendritic cells, but also it indirectly effects on T cell response by suppress the innate immunity. This review focuses on the current knowledge of the immune regulatory modulations of IL-10 and IL-35 to understand the potential therapeutic consequences of RA for further prospective studies.

**Keywords:** Rheumatoid arthritis; IL-10; IL-35; iTr35; IL-35 $^+$  $B_{Reg}$ ; Cytokines; Immunoregulation

## INTRODUCTION

Rheumatoid Arthritis (RA) is a progressive inflammatory autoimmune disease with articular and systemic effects with unknown cause but recent findings suggest a genetic basis for disease development [1]. The rheumatoid joint contains numerous cell types that are involved in these inflammatory and destructive processes [2]. Synovitis is caused by the influx or local activation, or both, of mononuclear cells (including T cells, B cells, etc.) and by angiogenesis. The synovial lining then becomes hyperplastic, and the synovial membrane expands and forms villi. The osteoclast-rich portion of the synovial membrane, or pannus, destroys bone, whereas enzymes secreted by neutrophils, synoviocytes and chondrocytes degrade cartilage [3].

T cells, B cells and the orchestrated interaction of pro-inflammatory cytokines play key roles in the pathophysiology of RA [3,4]. The cytokines most directly implicated in this process are TNF- $\alpha$  and IL-6; IL-1 and IL-17 may also play important roles in the disease prognosis [3]. To prevent inflammatory diseases, some therapeutic methods including chemical drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)), molecular target drugs (Disease-Modifying Anti-Rheumatic Drugs (DMARDs)), and surgery have been developed. However, these methods revealed many problems; i.e., high cost and insufficient effect [5,6].

There is thus a need to investigate more effective treatments for RA. Several studies investigate the negative regulatory function of Interleukin-35 (IL-35) and IL-10 in autoimmune diseases. B cells generally considered to have dual regulatory functions. Their capability to produce antibodies, antigen presentation as well as other functions in immune responses modulation, make them as positive regulators. However, different B cell subsets i.e.  $B_{Reg}$ , can also negatively regulate immunity either by cell contact-dependent mechanism or by regulatory cytokines secretion [7]. B cells functions have been observed in mice lacking B cells which suffered from severe Encephalomyelitis (EAE), a mouse model indicated the regulatory properties of B cells [8]. Furthermore, in RA patients, psoriasis was developed after B cell depletion with rituximab [9]. This regulatory function was primarily associated with IL-10 as it protects from autoimmune diseases [10, 11] until IL-35-producing B cell have been identified as a negative regulator [11]. This was confirmed by IL-10-independent immune inhibition in mouse models [12,13].

IL-35 regulatory roles had been investigated severally in RA models. It showed to induce different Regulatory T cell ( $T_{Reg}$ ) cell subsets which have suppressive activity against pro-inflammatory

mediators. On the other hand, IL-35 dealt with Helper T cell ( $T_H17$ ) proliferation inhibition as well as attenuation of RA progression [14-17].

Natural regulatory T cells ( $nT_{Reg}$ ) were specifically identified as a CD4 $^+$  CD25 $^+$  Foxp3 T cells [18] and were found to suppress effector immune responses including CD4 $^+$  and CD8 $^+$  T cells, dendritic cells as well as macrophages. However,  $nT_{Reg}$  considers a mediator of self-tolerance, it is not the primary one encountered in the periphery where another cells class were identified as inducible  $T_{Reg}$  ( $iT_{Reg}$ ) to mediate tolerance against pathogens and other antigens. Either, it has been recorded that  $T_{Reg}$  and  $B_{Reg}$  cells expanded and converted into a subpopulation iTr35 [19]; and IL-35 $^+$  $B_{Reg}$  cells by the action of IL-35, a potent cytokine generated from both  $T_{Reg}$  and  $B_{Reg}$  cells [20].

## IL-35-DEPENDENT REGULATION

IL-35 is the latest member of IL-12 family of heterodimeric cytokines. Opposed to other family members, IL-35 was identified as a potent immunosuppressive cytokine [19,21]. It composes of Eb13 (Epstein-Barr virus-induced gene 3), a  $\beta$  chain subunit encoded by IL27b, and p35  $\alpha$  subunit encoded IL12 $\alpha$  [22,23]. IL-35 is signaling through a unique IL-12R  $\beta$  2:gp130 heterodimer receptor, gp130:gp130 or IL-12R  $\beta$  2:IL-12R  $\beta$  2 homodimers. This signaling pathway depends on STAT1 and STAT4 transcription factors that bind to specific sites on IL27b and IL12  $\alpha$  promoters and promote their transcription. Thus, the anti-inflammatory capability may be referred to the STAT1:STAT4 heterodimerization [19].

Another study revealed that IL-35 signals activates STAT1, STAT3 and STAT4 in T cells while STAT1 and STAT3 are preferentially activated in B cells [20]. It was reported that IL-35 be secreted by  $T_{Reg}$  [24,22] and activated  $B_{Reg}$  [11] (Table 1). As well, IL-35 promotes the suppressive function of  $T_{Reg}$  and optimize homeostasis *in vitro* and *in vivo* [22], as it induces naïve T cells conversion into iTr35 cells that maintain immune tolerance [24]. IL-35 production by B cells (IL-35 $^+$  $B_{Reg}$ ) was triggered by the high active effector CD4 $^+$ T cells and macrophages beside their role as Antigen Presenting Cells (APCs) [11], which results in further B cells differentiation into  $B_{Reg}$  that secrete IL-10 [11,20].

## IL-35/ $T_{Reg}$ / iTr35

$iT_{Reg}$  be activated from naïve one in an immunosuppressive environment in the periphery then, they gain their suppressive and immune regulatory functions. They maintain their functional mechanisms through various surface molecules such as CTLA-4 or PD-1 while other populations mediate the suppressive role by



**Table 1:** IL-35 producing cell subsets.

Cell type	Phenotype	Features	Reference
nT <sub>Reg</sub>	CD4 <sup>+</sup> CD25 <sup>+</sup> Foxp3	- Suppress CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells, DCs and macrophages. - Mediate self-tolerance.	[18]
T <sub>Reg</sub>	CD8 <sup>+</sup> CTLA-4 <sup>+</sup>	- Suppress effector T cells	[24,33]
iT <sub>Reg</sub>	iTr35	- IL-35-dependent stimulation - Suppress CD4 <sup>+</sup> T cells	[29]
Plasma cell	CD138 <sup>hi</sup> B220 <sup>+</sup>	- Suppress effector T cells - Suppress NK cells	[11]
B <sub>Reg</sub>	IL-35 <sup>+</sup>	- IL-35- and IL-10-dependent stimulation - Suppress effector T cells	[20]

utilizing TGF-β and minimal secreting of IL-4 and IL-10 [26]. Dario Vignali and colleagues identified an inducible T<sub>Reg</sub> class, iT<sub>Reg</sub>35 that mediate suppression through the expression of regulatory cytokine IL-35 [22]. Several studies report that IL-35 has been expressed in thymus-derived and peripheral nT<sub>Reg</sub>s in either human and mice [21,27] while, Bardel et al. investigated that human Foxp3<sup>+</sup> or CD25<sup>+</sup> cells didn't express Ebi3 but in activated effector T cells. This study concerning stimulation of Ebi3 by CD3/CD28 in different CD4<sup>+</sup> T cell subsets and there was no detected Ebi3 in stimulated T<sub>Reg</sub> [28].

In a co-culture of conventional T cells (T<sub>Conv</sub>) with nT<sub>Reg</sub>, Collison, et al. [29]. in 2009 reported that higher levels of IL-35 has been expressed and T<sub>Conv</sub> have been converted into an IL-35-expressing inducible T<sub>Reg</sub>, iT<sub>Reg</sub>35. This conversion was IL-35- and IL-10-dependent till T<sub>Conv</sub> gained their regulatory function, then IL-10 was no longer required for their activity. Also, it has been confirmed that T<sub>Conv</sub> was converted into iT<sub>Reg</sub>35 in a contact-independent manner through the IL-35 activity. In the same study, T<sub>Reg</sub> showed maximal suppressive activity depending on both, IL-35 expression and contact with T<sub>Conv</sub> [21]. IL-35-dependent iT<sub>Reg</sub>35 given that the nature of these induced regulatory cells which though to be transient, they depend on their microenvironment through gaining their immunosuppressive phenotype [25]. From the fact that iT<sub>Reg</sub>35 has been naturally generated following the onset of various infectious and autoimmune diseases, IL-35 levels showed to be modest in the spleen whereas there was a significant increase in the infection site [24].

In addition to suppressive activity of T<sub>Reg</sub> by cytokines secretion, it also maintains their action by cell-cell contact with target cells or APCs [30,29]. *In vitro* T<sub>Reg</sub>-mediated suppression studies suggested that it is a contact-dependent process and there are no cytokines required [30,31] however *in vivo* studies indicated that secreted cytokines are important mean in T<sub>Reg</sub>-mediated suppression [29,32]. Collison, et al. [29] confirmed that T<sub>Reg</sub> optimal suppressive activity is potentiated by signaling pathway with conventional T cells including inhibitory cytokines, IL-35 and IL-10<sup>low</sup>, secretion. Another cellular subset, CD8<sup>+</sup>CTLA-4<sup>+</sup> T<sub>Reg</sub>, maintain their suppressive activity in a contact-independent but IL-35-dependent manner [33].

**IL-35/ B<sub>Reg</sub> /IL-35<sup>+</sup> B<sub>Reg</sub>**

B cells' suppressive activity was maintained through Toll-Like Receptors (TLR). TLR4 and CD40 were established as the mediators of B cells regulatory functions in EAE [34] while, CD40 alone was the main contributor in B cells protective role in RA [35]. Among genetic analysis of B cells, p35 and Ebi3 were showed to be expressed [36] upon activation by CD40 and TLR4 together through antigen engagement

resulted in IL-35 secretion [11]. B cells activity involve IL-10 as well as IL-35 secretion which protect and suppress autoimmune diseases. As IL-35 is produced by nT<sub>Reg</sub> and contributes to their suppressive activities, as it is produced by B cells and induces their conversion to B<sub>Reg</sub> for suppressive activities [22,21]. Furthermore, IL-35 induces *in vivo* B<sub>Reg</sub> conversion into another subset of IL-35<sup>+</sup>B<sub>Reg</sub> [20].

Despite there is no observed unique markers that exclusively identified B<sub>Reg</sub> [37], in autoimmune uveitis there was B<sub>Reg</sub> phenotype, CD1d<sup>hi</sup>CD5<sup>+</sup> B<sub>Reg</sub>, that shown to suppress inflammation in contact manner [38,20]. In the same study, rIL-35 induced B220<sup>+</sup> B cells suppression and CD19<sup>+</sup>CD5<sup>+</sup>B220<sup>low</sup> B<sub>Reg</sub> expansion *in vivo* [20]. CD138<sup>hi</sup> plasma cell subset that provide IL-35 and IL-10 during *Salmonella* infection, has been identified by Shen and colleagues [11]. Unlike iT<sub>Reg</sub>35 suppressive activity that is mediated by IL-35 without IL-10, IL-35<sup>+</sup>B<sub>Reg</sub> requires the both IL-35 and IL-10 signals for suppressive functions [24,20].


**IL-35 modes of action**

In RA mouse model, Collagen-Induced Arthritis (CIA), a study confirming the possibility of IL-35 participation in autoimmune disease. Recombinant IL-35 (rIL-35) showed to expand CD4<sup>+</sup>CD25<sup>+</sup> T<sub>Reg</sub> cells, suppress the proliferation of effector T cells and attenuate T<sub>H</sub>17 polarization and IL-17 production [23,15] (Figure 1). Kochetkova and colleagues found that rIL-35 administration resulted in the frequency of CD4<sup>+</sup>CD39<sup>+</sup>T<sub>Reg</sub> subset that express Foxp3 and IL-10, which promoted their proliferation. These cell subsets could protect CIA animal model in IL-10-dependent manner [15]. Active RA patients have a reduced level of T<sub>Reg</sub> suppressive activity towards pro-inflammatory cytokines production by effector T cells [17,14]. A study concerned with the role of IL-35 in T cells of RA patients, Nakano et al. reported that IL-35 secretion was reduced in active RA compared with healthy controls. Also, this *in vitro* study revealed that recombinant human IL-35 enhanced nT<sub>Reg</sub> function and suppress T<sub>H</sub>17 in RA patients [16]. In addition, recombinant IL-35 clearly showed to increase antibodies titers [15], its ability to act on other subsets reflect its contribution to humoral immunity [33]. However, there is a decisive difference between IL-35 and IL-27, a member from the same family that share Ebi3 and has a suppressive activity [39], IL-35 was more efficient in CIA suppression while IL-27 could act at the disease onset only [23].

In contrast to IL-35-dependent suppression in inflammatory diseases like arthritis, tumor models showed that it contributes to tumor genesis through immune-directed and tumor-directed activities. IL-35 potentially promotes angiogenesis that induce tumor cell proliferation, however on the other hand, it may have anti-tumor activity by suppressing tumor cell infiltration [24,20]. Several diseases showed to be associated with high IL-35 levels like coronary artery disease and cancer e.g. acute myeloid leukemia [40]. This is might due to the decrease in immune response, in CIA model, rIL-35 attenuate the severity of arthritis and on the other hand, it showed to collapse the inflammatory response [15,23].

**IL-10-DEPENDENT REGULATION**

There are different B cell subsets showed to secret IL-10 in health and disease [Table 2]. Earlier, B-1 phenotype considered the major IL-10 producer [41] and upon IL-12 stimulation of B-1a cells (CD5<sup>+</sup>B cells) [42]. Moreover, B cell types originated in the Marginal Zone (MZ B) and its Transitional Precursor (T2-MZP) with the phenotype CD19<sup>+</sup>CD23<sup>+</sup>CD21<sup>+</sup>CD1d<sup>hi</sup> [38,43] are capable of producing IL-10 in



**Figure 1:** Immunoregulatory functions of IL-35 and IL-10. The possibility by which IL-35 and IL-10 modulate immune responses may include the following: Promote  $T_{Reg}$  expansion, suppress  $T_H1$ ,  $T_H17$ ,  $CD8^+$  cytotoxic T cells and monocytes differentiation and can Dampen Dendritic Cells (DCs) activation.

Cell type	Phenotype	Features	Reference
$T_{Reg}$	$CD4^+CD39^+$	- IL-35-dependent stimulation	[15]
Immature B cells	$CD19^+CD24^{hi}CD38^{hi}$	- Induce $T_{Reg}$ cells - Suppress $T_H1$ and $T_H17$	[45]
B10	$CD24^{hi}CD27^+$ (Human)	- Suppress effector T cells - Suppress DCs	[46-48]
B10	$CD1d^{hi}CD5^+$ (Mouse)	- Suppress effector T cells - Suppress DCs	[38]
B-1a	$CD5^+$	- IL-12-dependent stimulation	[42]
T2-MZP	$CD19^+CD23^+CD21^+CD1d^{hi}$	- Induce $T_{Reg}$ cells - Suppress effector T cells	[43,38]
MZ	$CD19^+CD21^{hi}CD23^-$	- Induce $T_{Reg}$ cells - Suppress effector T cells	[43,57,58,]
Plasma cells	$CD138^{hi}B220^+$	- Suppress effector T cells - Suppress NK cells	[11]
$B_{Reg}$	$CD19^+CD5^+B220^o$	- IL-35-dependent stimulation	[20]

lupus [44] and arthritis [43], respectively. Another IL-10-producing B cell phenotype was identified as  $CD1d^{hi}CD5^+ B10$  that shares typical markers with B-1a, MZ B and T2-MZP cells [38]. Immature B cells showed a response toward CD40 stimulation and converted into IL-10-producing phenotype,  $CD19^+CD24^{hi}CD38^{hi}$  B cells in the peripheral of healthy individuals [45]. Although CD27 is a phenotypic marker of human memory B cells,  $CD27^+$  B cells could expand and act as a biomarker in autoimmune diseases e.g.  $CD24^{hi}CD27^+$  B10 in RA [46-48].

### IL-10 induction signals

However, there is no distinct studies concerning identification of specific surface markers in human or mouse  $B_{Reg}$  [7], EAE model suggested that TLRs as a part of the microenvironment are involved in modulation  $B_{Reg}$  function [49]. Combined together, TLR stimulation, BCR and CD40 ligation result in further amplification of IL-10-producing cell subsets for further IL-10 production and an effective suppression [49]. In human B cells, Bouaziz and colleagues reported that IL-10 production depends on TLR9 signaling which is a CpG (synthetic TLR9 agonist) receptor [50]. Other signals that might contribute in IL-10 production by B cells include B-Cell Activating Factor (BAFF) which could induce  $CD1d^{hi}CD5^+ B$  cells to secrete IL-10 [51], as well as *in vivo* induction of  $CD4^+Foxp3^+$  T cells to suppress



effector T cell in B cell-dependent manner [52]. Either, apoptotic cells act as endogenous IL-10 inducer that further induces T cells to secrete IL-10 in CIA model [53]. In 2012, Qian, et al. [54] investigated that dendritic cells have a crucial regulatory role as B cell inducer to produce IL-10.

### IL-10 modes of action

Naturally expressed IL-10 by  $B_{Reg}$  is very low while it could be expanded *in vitro* for further immune suppression. IL-10 has shown to suppress T cell proliferation as well as inflammatory cytokines production by  $T_H1$  [38,43,51] [Figure 1]. Also, it has been demonstrated that IL-10 inhibits  $T_H17$  through decreasing STAT3 phosphorylation and ROR $\gamma$ t reduction [55]. Dendritic cells could be promoted to secrete IL-4 and reduce IL-12 resulted in  $T_H1/T_H2$  imbalance in IL-10-dependent manner [56]. Either,  $B_{Reg}$  produced IL-10 promotes  $CD4^+CD25^+Foxp3^+$   $T_{Reg}$  infiltration to suppress inflamed airway [53,57, 58].

### RECENT APPLICATIONS

The accumulation of the Mesenchymal Stem Cells (MSCs) in the inflammation sites have shown that they can inhibit immune responses as well as induction of immune components *in vitro* and *in vivo* [59,60]. Regarding these characteristics, MSCs could be immersed as a vehicle for drugs and genes delivery, a cell-based immunotherapy [61]. Previous studies reported the efficacy of MSCs for IL-10 [62] and Foxp3 [63] overexpression. Recently, a transfected MSCs with a lent virus vector for overexpression of murine IL-35 for therapeutic immunosuppressive function investigated their ability to suppress  $CD4^+$  T cells [64]. There are further applications for prospective immunotherapies techniques concerning more future studies among IL-10 and IL-35 regulatory mechanisms' components and pathways.

### CONCLUSION

Nowadays, there is a great eager for the evaluation of new immunotherapies. IL-35 and IL-10 are potent immune regulatory cytokines in autoimmune and infections. They perform their roles through expanding the suppressive functions of T and B lymphocytes. IL-35 is produced by  $nT_{Reg}$  and activated  $B_{Reg}$ ; and by the STATs signals, it has shown to auto regulate its precursors conversion into IL-35-producing cells,  $iTr35$  and  $IL-35^+ B_{Reg}$ . This results in further expansion and IL-35 production for maintaining more suppressive activities. IL-35 restrict  $T_H1$  and  $T_H17$  differentiation in RA models and other autoimmune and inflammatory diseases. Although only a few human studies are available showing IL-10-dependent immune suppression in RA, mouse models confirm the therapeutic role of IL-10 in CIA. IL-10 is produced naturally by different B and T cells phenotypes as well as it could be induced *in vitro* for further suppressive functions. Also, IL-10 inhibits  $T_H17$  proliferation through STATs signals and induces  $T_{Reg}$  expansion. Depending on these findings and the unknown causes of rheumatoid arthritis, there must be further future focusing on the dynamics and process of generation of regulatory cells and cytokines.

### ACKNOWLEDGMENT

We acknowledge Tanta University for generous supplying and the Biochemistry unit members for helpful discussions and supporting data.

### REFERENCES

- Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. *Rheumatology* 51 (suppl\_5):3-11. <https://goo.gl/Fs5ewJ>
- Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol.* 1996; 14: 397-440. <https://goo.gl/zS8vN7>
- Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. *Nat Rev Drug Discov.* 2003; 2: 473-88. <https://goo.gl/NVzh1n>
- Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. *Lancet.* 2007; 370: 1861-1874. <https://goo.gl/hyiq9H>
- Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. *PLoS One.* 2009; 4: 7556. <https://goo.gl/tpUJzq>
- Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. *Nat Rev Drug Discov.* 2007; 6: 75-92. <https://goo.gl/PgNWdc>
- Yang M, Rui K, Wang S, Lu L. Regulatory B cells in autoimmune diseases. *Cell and Mol Immunol.* 2013; 10: 122-132. <https://goo.gl/SPGBmW>
- Wolf SD, Dittel BN, Hardardottir F, Janeway CA. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. *J Exp Med.* 1996; 184: 2271-2278. <https://goo.gl/6RLpdM>
- Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. *Arthritis Rheum.* 2007; 56: 2715-2718. <https://goo.gl/iSe7V4>
- Fillatreau S. Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection. *Immunol Rev.* 2011; 240: 52-71. <https://goo.gl/WZwNEZ>
- Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al, Jaimes Y, Daridon C. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. *Nature.* 2014; 507: 366-370. <https://goo.gl/aw5bLo>
- Wilson MS, Taylor MD, O'Gorman MT, Balic A, Barr TA, Filbey K, et al. Helminth-induced  $CD19^+ CD23hi$  B cells modulate experimental allergic and autoimmune inflammation. *Eur J Immunol.* 2010; 40: 1682-1696. <https://goo.gl/6qms89>
- Su Y, Zhang A-H, Noben-Trauth N, Scott DW. B-cell gene therapy for tolerance induction: host but not donor B-cell derived IL-10 is necessary for tolerance. *Front Microbiol.* 2011; 2: 154. <https://goo.gl/6qzDWR>
- Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF $\alpha$  therapy. *J Exp Med.* 2004; 200: 277-85. <https://goo.gl/rhrdN8>
- Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of  $CD39^+$  regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. *J Immunol.* 2010; 184: 7144-7153. <https://goo.gl/MMdccc>
- Nakano S, Morimoto S, Suzuki S, Tsushima H, Yamanaka K, Sekigawa I, et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. *Rheumatology.* 2015; 54: 1498-1506. <https://goo.gl/ABgqs6>
- Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human  $CD4^+ CD25^+$  hi T-regulatory cells. *Blood.* 2006; 108: 253-261. <https://goo.gl/Swmfuj>
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor  $\alpha$ -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol.* 1995; 155: 1151-64. <https://goo.gl/yzaseK>
- Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. *Nat Immunol.* 2012; 13: 290-299. <https://goo.gl/HQiaD5>
- Wang R-X, Yu C-R, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress CNS autoimmune disease. *Nat Med.* 2014; 20: 633-641. <https://goo.gl/nhh2qT>



21. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DAA. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. *The Journal of Immunology*. 2011; 186: 6661-6666. <https://goo.gl/izStW1>
22. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature*. 2007; 450: 566-569. <https://goo.gl/ZUIwLr>
23. Niedbala W, Wei X-q, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. *Eur J Immunol*. 2007; 37: 3021-3029. <https://goo.gl/HxUF3r>
24. Collison LW, Chaturvedi V, Henderson AL, Giacomini PR, Guy C, Bankoti J, et al. L-35-mediated induction of a potent regulatory T cell population. *Nat immunol*. 2010; 11: 1093-1101. <https://goo.gl/vfLfy9>
25. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. *Front Immunol*. 2013; 4: 315. <https://goo.gl/7GuxHi>
26. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, LeVings MK. Type 1 T regulatory cells. *Immunol Rev*. 2001; 182: 68-79. <https://goo.gl/fGrCdw>
27. Kaser T, Müllebnner A, Hartl RT, Essler SE, Saalmüller A, Duvigneau J. Porcine T-helper and regulatory T cells exhibit versatile mRNA expression capabilities for cytokines and co-stimulatory molecules. *Cytokine*. 2012; 60: 400-409. <https://goo.gl/ievAym>
28. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Hermine A, Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. *J Immunol*. 2008; 181: 6898-905. <https://goo.gl/MTT7HB>
29. Collison LW, Pillai MR, Chaturvedi V, Vignali DAA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. *J Immunol*. 2009; 182: 6121-6128. <https://goo.gl/EM74pr>
30. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. *Nat Immunol*. 2006; 7: 83-92. <https://goo.gl/x62uiT>
31. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4+ CD25+ T cells with regulatory properties from human blood. *J Exp Med*. 2001; 193: 1303-1310. <https://goo.gl/zaXqjo>
32. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+ CD25<sup>high</sup>Foxp3+ T cells secreting interleukin-10 and transforming growth factor- $\beta$  mediates suppression in the tumor microenvironment. *Clin Cancer Res*. 2007; 13: 4345-54. <https://goo.gl/yfjzoi>
33. Olson BM, Jankowska-Gan E, Becker JT, Vignali DAA, Burlingham WJ, McNeel DG. Human Prostate Tumor Antigen-Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade. *J Immunol*. 2012; 189: 5590-5601. <https://goo.gl/48WGPY>
34. Fillatreau S, Sweeney CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. *Nature immunology*. 2002; 3: 944-950. <https://goo.gl/7ycX94>
35. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. *J Exp Med*. 2003; 197: 489-501. <https://goo.gl/CnW7dn>
36. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. *Proc Natl Acad Sci U S A*. 1997; 94: 12041-12046. <https://goo.gl/oac5fH>
37. Mauri C, Bosma A. Immune regulatory function of B cells. *Annu Rev Immunol*. 2012; 30: 221-41. <https://goo.gl/YEKWzC>
38. Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1d hi CD5+ phenotype controls T cell-dependent inflammatory responses. *Immunity*. 2008; 28: 639-650. <https://goo.gl/vSQAUF>
39. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. *Nat Immunol*. 2006; 7: 929-36. <https://goo.gl/3wtq4x>
40. Wu H, Li P, Shao N, Ma J, Ji M, Sun X, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF- $\beta$  in acute myeloid leukemia. *Oncol Lett*. 3: 1119-1123. <https://goo.gl/xq6c1Y>
41. O'Garra A, Chang R, Go N, Hastings R, Haughton G, Howard M. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. *Eur J Immunol*. 1992; 22: 711-717. <https://goo.gl/RgwYoZ>
42. Spencer NF, Daynes RA (1997) IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5-B cells: possible involvement in age-associated cytokine dysregulation. *Int Immunol*. 1997; 9: 745-54. <https://goo.gl/Ruas1W>
43. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. *J Immunol*. 2007; 178: 7868-7878. <https://goo.gl/8zcYKD>
44. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. *J Clin Immunol*. 2005; 25: 29-40. <https://goo.gl/bXGQVA>
45. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19+ CD24 hi CD38 hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. *Immunity*. 2010; 32: 129-40. <https://goo.gl/Nfu46E>
46. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. *Blood*. 2011; 117: 530-41. <https://goo.gl/zCNMqh>
47. Sanz I, Wei C, Lee FE-H, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. *Semin Immunol*. 2008; 20: 67-82. <https://goo.gl/AUFjma>
48. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. *Immunol Today*. 2000; 21: 204-206. <https://goo.gl/npSfz7>
49. Lampropoulou V, Hoehlig K, Roch T, Neves P, Gomez EC, Sweeney CH, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. *J Immunol*. 2008; 180: 4763-73. <https://goo.gl/QRNiJj>
50. Bouaziz J-D, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, Bensussan A, et al. IL-10 produced by activated human B cells regulates CD4+ T-cell activation in vitro. *European journal of immunology*. 2010; 40: 2686-2691. <https://goo.gl/d6Tgru>
51. Yang M, Sun L, Wang S, Ko K-H, Xu H, Zheng B-J, et al. Novel function of B cell-activating factor in the induction of IL-10-Producing regulatory B cells. *J Immunol*. 2010; 184: 3321-3325. <https://goo.gl/WX6RdH>
52. Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D, et al. Increased CD4+ Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. *J Immunol*. 2009; 182: 793-801. <https://goo.gl/TUviWd>
53. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. *Proc Natl Acad Sci U S A*. 2007; 104: 14080-14085. <https://goo.gl/WDBMv6>
54. Qian L, Qian C, Chen Y, Bai Y, Bao Y, Lu L, et al. Regulatory dendritic cells program B cells to differentiate into CD19 hi Fc $\gamma$ IIb hi regulatory B cells through IFN- $\beta$  and CD40L. *Blood*. 2012; 120: 581-91. <https://goo.gl/ZHwjVS>
55. Yang M, Deng J, Liu Y, Ko K-H, Wang X, Jiao Z, et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. *Am J Pathol*. 2012; 180: 2375-85. <https://goo.gl/EcFNfv>
56. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo. *J Exp Med*. 2000; 192: 475-82. <https://goo.gl/xFCVJA>
57. Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. *J Immunol*. 2009; 182: 3492-3502. <https://goo.gl/j1tQKS>
58. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. *J Immunol*. 2011; 186: 5569-5579. <https://goo.gl/Mi4ATJ>
59. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. *Eur J Immunol*. 2006; 36: 2566-73. <https://goo.gl/XV3789>



60. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scand J Immunol.* 2003; 57: 11-20. <https://goo.gl/ok8FLh>
61. Greco SJ, Rameshwar P. Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. *Ther Deliv.* 2012; 3: 997-1004. <https://goo.gl/ZtQrkP>
62. Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2007; 39: 637-645. <https://goo.gl/ef5btg>
63. Qi H, Chen G, Huang Y, Si Z, Li J. Foxp3-modified bone marrow mesenchymal stem cells promote liver allograft tolerance through the generation of regulatory T cells in rats. *J Transl Med.* 2015; 13: 274. <https://goo.gl/WLtv3u>
64. Zhao N, Li H, Yan Y, Jiang R, He X. Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4+ T cell function. *Cell Immunol.* 2017; 312: 61-66. <https://goo.gl/J7CDAQ>